1. Cell Cycle/DNA Damage
    Metabolic Enzyme/Protease
  2. PDI


PDI (Protein disulfide isomerases) is a 55-kDa protein and consists of four domains namely a, b, b', a'. PDI is an abundant enzyme in the endoplasmic reticulum (ER). PDI, a prototypic thiol isomerase, is an important oxidase, reductase, isomerase and molecular chaperone. It can distinguish between partially folded, unfolded, and properly folded protein substrates, and catalyze the formation and cleavage of thiol-disulfide bonds during protein folding in the ER. PDI can also maintain active conformation of the β subunit of collagen prolyl 4-hydroxylase and stabilization of the major histocompatibility complex's (MHC) class 1 peptide loading complex (PLC). PDI expression is up-regulated in select types of cancers[1][2].

PDI Related Products (10):

Cat. No. Product Name Effect Purity
  • HY-111117
    3-Methyltoxoflavin 99.64%
    3-Methyltoxoflavin is a potent Protein disulfide isomerase (PDI) inhibitor, with an IC50 of 170 nM.
  • HY-100432
    LOC14 is a potent Protein disulfide isomerase (PDI) inhibitor with EC50 and Kd values of 500 nM and 62 nM, respectively. LOC14 exhibits high stability in mouse liver microsomes and blood plasma, low intrinsic microsome clearance, and low plasma-protein binding[1]. LOC14 inhibits PDIA3 activity, decreases intramolecular disulfide bonds and subsequent oligomerization (maturation) of HA in lung epithelial cells[3].
  • HY-122895
    E64FC26 Inhibitor 98.10%
    E64FC26 is a potent pan-inhibitor of the protein disulfide isomerase (PDI) family, with IC50s of 1.9, 20.9, 25.9, 16.3, and 25.4 μM against PDIA1, PDIA3, PDIA4, TXNDC5, and PDIA6, respectively. E64FC26 shows anti-myeloma activity[1].
  • HY-100430
    CCF642 Inhibitor
    CCF642 is a potent protein disulfide isomerases (PDI) inhibitor with an IC50 of 2.9 μM. CCF642 causes acute endoplasmic reticulum (ER) stress in multiple myeloma cells accompanied by apoptosis-inducing calcium release. CCF642 has broad anti-multiple myeloma activity[1].
  • HY-W107464
    G6PDi-1 99.81%
    G6PDi-1 is a reversible and non-competitive glucose-6-phosphate dehydrogenase (G6PD) inhibitor with an IC50 of 0.07 μM. G6PDi-1 depletes NADPH most strongly in lymphocytes. G6PDi-1 markedly decreases inflammatory cytokine production in T cells[1].
  • HY-142127
    Ribostamycin Inhibitor
    Ribostamycin (Vistamycin) is a broad-spectrum aminoglycoside antibiotic. Ribostamycin is effective against Gram-Negative and Gram-Positive bacterial infection. Ribostamycin also inhibits the chaperone activity of PDI[1][2].
  • HY-117570
    KSC-34 99.35%
    KSC-34, a covalent modifier of protein disulfide isomerase A1 (PDIA1), is also a selective and potent a-site inhibitor of PDIA1 with an IC50 of 3.5 μM. KSC-34 displays a 30-fold selectivity for a domain over a′ domain and displays high selectivity for PDIA1 in complex proteomes with minimal engagement of other members of the PDI family[1].
  • HY-100433
    PACMA 31
    PACMA 31 is an irreversible, orally active protein disulfide isomerase (PDI) inhibitor with an IC50 of 10 μM. PACMA 31 forms a covalent bond with the active site cysteines of PDI. PACMA 31 shows tumor targeting ability and significantly suppresses ovarian tumor growth without causing toxicity to normal tissues[1].
  • HY-114086
    ML359 99.08%
    ML359 is a potent, selctive and reversible inhibitor of protein disulfide isomerase (PDI), with an IC50 of 250 nM. ML359 can prevent thrombus formation in vivo[1][2].
  • HY-B1228
    Ribostamycin sulfate Inhibitor 99.84%
    Ribostamycin sulfate (Vistamycin sulfate) is a broad-spectrum antimicrobial, inhibits bacterial protein synthesis at the level of 30S and 50S ribosomal subunit binding, also inhibits the chaperone activity of protein disulfide isomerase (PDI), used in pharmacokinetic and nephrotoxicity studies